STR-I-231-MTMX
INSRMe012-A
General
Cell Line |
|
hPSCreg name | INSRMe012-A |
Cite as: | INSRMe012-A (RRID:CVCL_C090) |
Alternative name(s) |
STR-I-231-MTMX
|
Cell line type | Human embryonic stem cell (hESC) |
Similar lines |
|
Last update | 3rd September 2022 |
User feedback | |
Provider |
|
Generator |
INSERM (INSRM)
Contact:
Ontogeny of primordial germ cells |
Derivation country | France |
External Databases |
|
Cellosaurus | CVCL_C090 |
Wikidata | Q54970624 |
General Information |
|
Publications | |
* Is the cell line readily obtainable for third parties? |
Yes |
Donor Information
General Donor Information |
|
Sex | male |
Phenotype and Disease related information (Donor) |
|
Diseases | A disease was diagnosed.
|
Disease associated phenotypes |
|
Ethics
Alternatives to consent are available? | Yes |
Alternatives to consent | |
Alternative consent approval number | |
How may genetic information associated with the cell line be accessed? |
hESC Derivation
Embryo stage | Blastula with ICM and Trophoblast |
PGD Embryo? |
Yes |
ZP removal technique | Enzymatic |
Culture Conditions
Surface coating | Gelatin | |||||||||
Passage method | Mechanically | |||||||||
CO2 Concentration | 5 % | |||||||||
Medium |
Other medium:
Base medium: Knockout-DMEM
Main protein source: Knock-out serum replacement Serum concentration: 20 % Supplements
|
Characterisation
Analysis of Undifferentiated Cells
Marker | Expressed | Immunostaining | RT-PCR | Flow Cytometry | Enzymatic Assay | Expression Profiles |
DNMT3B |
Yes |
|
||||
GABRB3 |
Yes |
|
||||
GDF3 |
Yes |
|
||||
POU5F1 (OCT-4) |
Yes |
|
||||
SOX2 |
Yes |
|
||||
TDGF1 |
Yes |
|
||||
SSEA-1 |
No |
|
||||
SSEA-4 |
Yes |
|
||||
TRA 1-81 |
Yes |
|
Differentiation Potency
Microbiology / Virus Screening |
|
HIV 1 | Negative |
HIV 2 | Negative |
Hepatitis B | Negative |
Hepatitis C | Negative |
Genotyping
Karyotyping (Cell Line) |
|
Has the cell line karyotype been analysed? |
Yes
46XY
Passage number: 12
|
Other Genotyping (Cell Line) |
Login to share your feedback, experiences or results with the research community.